Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
$5.81
+1.4%
$5.02
$3.56
$12.92
$327.88M0.41364,933 shs188,854 shs
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
$6.59
+2.0%
$6.03
$4.35
$12.38
$329.76M0.45210,081 shs127,517 shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$7.64
+2.7%
$6.54
$4.58
$9.78
$384.05M1.89512,764 shs190,914 shs
HilleVax, Inc. stock logo
HLVX
HilleVax
$2.06
-2.6%
$1.93
$1.34
$14.22
$103.29M0.76465,803 shs59,470 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
0.00%+4.31%+10.04%+24.68%-35.44%
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
0.00%+4.94%+7.33%+21.36%-4.49%
CryoPort, Inc. stock logo
CYRX
CryoPort
0.00%+3.10%+23.62%+43.07%+22.04%
HilleVax, Inc. stock logo
HLVX
HilleVax
0.00%+4.31%+3.79%+44.72%-85.43%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
1.9439 of 5 stars
3.61.00.00.02.31.70.0
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
1.9096 of 5 stars
3.61.00.00.00.63.30.0
CryoPort, Inc. stock logo
CYRX
CryoPort
2.5232 of 5 stars
3.42.00.00.03.22.50.0
HilleVax, Inc. stock logo
HLVX
HilleVax
3.2346 of 5 stars
3.03.00.00.02.43.31.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
3.25
Buy$30.00416.35% Upside
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
3.25
Buy$22.00233.84% Upside
CryoPort, Inc. stock logo
CYRX
CryoPort
2.71
Moderate Buy$11.0043.98% Upside
HilleVax, Inc. stock logo
HLVX
HilleVax
2.00
Hold$3.0045.99% Upside

Current Analyst Ratings Breakdown

Latest HLVX, AURA, CYRX, and ATXS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/13/2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
5/28/2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$22.00
5/23/2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$19.00
5/14/2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$47.00 ➝ $47.00
5/8/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
5/5/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $7.00
4/29/2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/28/2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$47.00
4/16/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
4/16/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/10/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
N/AN/AN/AN/A$3.97 per shareN/A
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/AN/AN/AN/A$3.04 per shareN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
$228.38M1.68N/AN/A$7.44 per share1.03
HilleVax, Inc. stock logo
HLVX
HilleVax
N/AN/AN/AN/A$3.10 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
-$94.26M-$1.87N/AN/AN/AN/A-47.18%-31.26%8/11/2025 (Estimated)
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-$86.92M-$1.90N/AN/AN/AN/A-58.63%-49.74%8/14/2025 (Estimated)
CryoPort, Inc. stock logo
CYRX
CryoPort
-$114.76M-$2.34N/AN/AN/A-50.15%-11.03%-5.54%8/5/2025 (Estimated)
HilleVax, Inc. stock logo
HLVX
HilleVax
-$147.27M-$2.15N/AN/AN/AN/A-51.86%-41.45%8/14/2025 (Estimated)

Latest HLVX, AURA, CYRX, and ATXS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-$0.47-$0.55-$0.08-$0.55N/AN/A
5/13/2025Q1 2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
-$0.48-$0.58-$0.10-$0.58N/AN/A
5/8/2025Q1 2025
HilleVax, Inc. stock logo
HLVX
HilleVax
-$0.37-$0.12+$0.25-$0.12N/AN/A
5/7/2025Q1 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.23-$0.22+$0.01-$0.28$56.19 million$41.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
N/AN/AN/AN/AN/A
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/AN/AN/AN/AN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
HilleVax, Inc. stock logo
HLVX
HilleVax
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
N/A
17.39
17.39
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/A
11.06
11.06
CryoPort, Inc. stock logo
CYRX
CryoPort
0.51
5.56
5.24
HilleVax, Inc. stock logo
HLVX
HilleVax
N/A
25.32
25.32

Institutional Ownership

CompanyInstitutional Ownership
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
98.98%
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
96.75%
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
HilleVax, Inc. stock logo
HLVX
HilleVax
86.42%

Insider Ownership

CompanyInsider Ownership
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
4.50%
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
5.40%
CryoPort, Inc. stock logo
CYRX
CryoPort
10.00%
HilleVax, Inc. stock logo
HLVX
HilleVax
24.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
3056.43 million53.89 millionOptionable
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
5050.27 million47.55 millionNot Optionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.14 million45.12 millionOptionable
HilleVax, Inc. stock logo
HLVX
HilleVax
2050.14 million37.66 millionNot Optionable

Recent News About These Companies

HilleVax Reports Q3 Financial Results Amid Strategic Planning
What Makes HilleVax (HLVX) a New Buy Stock

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Astria Therapeutics stock logo

Astria Therapeutics NASDAQ:ATXS

$5.81 +0.08 (+1.40%)
As of 07/3/2025 02:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Aura Biosciences stock logo

Aura Biosciences NASDAQ:AURA

$6.59 +0.13 (+2.01%)
As of 07/3/2025 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

CryoPort stock logo

CryoPort NASDAQ:CYRX

$7.64 +0.20 (+2.69%)
Closing price 07/3/2025 01:29 PM Eastern
Extended Trading
$7.42 -0.22 (-2.81%)
As of 07/3/2025 04:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

HilleVax stock logo

HilleVax NASDAQ:HLVX

$2.06 -0.06 (-2.61%)
As of 07/3/2025 01:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.